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OBJECTIVES: Because limited data are available on changes in direct costs (medical 
and prescription) and likelihood of health service utilization among employees treated
with Interferon (IFN) â1a-IM for MS, the study aimed to assess the changes in direct
costs and likelihood of health service utilization for persons with multiple sclerosis
(MS) treated with IFN â1a-IM. METHODS: A health care claims database of US
employees from 2001–2008 was used to identify patients with MS (2 IFN â1a-IM 
prescriptions [Rxs] or an IFN â1a-IM Rx MS diagnosis [ICD-9  340.X]). Employees 
with eligibility 6 months before and after their initial IFN â1a-IM Rx and no other
disease-modifying therapies were included in the analysis. Non-parametric tests and 
t-tests were used to compare the mean and median direct medical costs and the likeli-
hood of health service utilization before and after initiation of IFN â1a-IM. RESULTS:
Data from 68 employees with MS that took IFN â1a-IM (42 employees with health
service utilization data) were eligible for analysis. All direct medical cost changes were
signiﬁ cant (P  0.01). Mean medical costs decreased by $2872 (54%) from $5339 to 
$2467 and median costs decreased by $3691 (80%) from $4596 to $905. Signiﬁ cant 
(P  0.05) decreases in the likelihood of health service utilization were noted for the 
following: 11.9% for emergency department from 11.9% to 0%, 23.8% for outpa-
tient hospital from 64.3% to 40.5%, and 16.7% for “other” (including home-care, 
ambulance, mobile unit, and unknown) from 31.0% to 14.3%. Inpatient hospital care 
decreased non-signiﬁ cantly (P  0.096) by 11.9% from 16.7% to 4.8%, while lab and 
ofﬁ ce claims stayed the same (7.1% and 92.9%, respectively). CONCLUSIONS:
Direct medical costs decreased for IFN â1a-IM patients after therapy initiation, with 
reduced use of emergency department, inpatient and outpatient hospital care, and 
other services. These differences suggest the costs of Interferon â1a-IM are partially 
offset by medical care saving.
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OBJECTIVES: To analyse the cost and cost-effectiveness of transanal colonic irriga-
tion (TAI) using a self-administered system compared to conservative bowel manage-
ment in spinal cord injury patients seen from a German perspective. METHODS: A
cost effectiveness model was developed based on a randomised controlled multicentre
trial conducted in 2003–2005, where 87 adult spinal cord injured patients with neu-
rogenic bowel dysfunction were allocated to 10 weeks with either TAI or conservative
bowel management. The sensitivity analysis was an extreme analysis based on conﬁ -
dence intervals, and estimates the results for best case and worst case scenarios. Cost 
variables (i.e. cost of constipation medication, treatment for urinary tract infections, 
products, labour of carer helping with bowel management and lost productivity of 
patients) were included and based on the clinical study results. Estimates of resources
and unit costs were made for the German health care system. Effect variables were 
drawn from the same clinical trial. RESULTS: When comparing outcome measures at 
termination, TAI signiﬁ cantly reduced symptoms of neurogenic bowel dysfunction.
For a 2-day period, product-related costs were higher for TAI (€16 vs. €4), however,
labour costs due to bowel management were lower (€6 vs. €9). For TAI, costs associ-
ated with urinary tract infections (€1 vs. €3) and patient time spent (€15 vs. €23) were 
reduced. Thus, the total cost to society was slightly lower when patients used TAI 
with a self-administered system (€38 vs. €39). The sensitivity analysis shows that costs
may range from €33 to €46 for TAI and from €33 to €46 for conservative bowel 
management. CONCLUSIONS: Transanal colonic irrigation reduces the symptoms of 
neurogenic bowel dysfunction and results in a slightly lower total cost to society than 
conservative bowel management. The total cost results were found to be robust in the 
sensitivity analysis.
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OBJECTIVES: Hydrocephalus is a disorder where cerebrospinal ﬂ uid (CSF) is unable 
to drain efﬁ ciently from the brain. Infants afﬂ icted often present with enlarged heads, 
and multiple complications can occur. The standard treatment is the relatively danger-
ous, complicated, and expensive surgical insertion of a shunt system to drain the ﬂ uid. 
It is the purpose of this project to explore possible contributing variables to the pres-
ence of the disease in infants and its relative costs. METHODS: Inpatients one-year-old
or younger afﬂ icted with hydrocephalus and an equally sized control group were 
extracted from the National Inpatient Sample (NIS) provided by the Agency for
Healthcare Research and Quality (AHRQ). The statistical data modeling software, 
SAS, was used for calculation of summary statistics, kernel density estimation, logistic
and linear regression, and production of ﬁ gures and charts. Exploratory data analysis
was used to examine the data in detail. RESULTS: It was determined that younger 
infants show higher mortality rates; additionally, males are more likely to present with 
hydrocephalus and cost slightly more on average than females despite the distribution 
curves for length of stay appearing virtually identical between genders. Diagnoses and 
procedures expected for non-hydrocephalic infants showed negative correlation in the 
logistic model. The linear model showed that low birth-weight signiﬁ cantly impacted 
length of stay when also present with hydrocephalus. Additionally, afﬂ iction with
hydrocephalus at admittance was strongly correlated with length of stay but not total 
costs, implying an impact on recovery time, but not additional treatments. CONCLU-
SIONS: The costs of health care in America are constantly rising, and infants often 
incur greater costs due to the need for sophisticated and advanced treatments. Hydro-
cephalus clearly exacerbates medical costs, and should warrant further study. Explor-
atory analysis can ﬁ nd important and relevant information about the disease.
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OBJECTIVES: Cholinesterase inhibitors (ChEIs), including rivastigmine, donepezil,
and galantamine, when taken as prescribed impact mild to moderate cognitive impair-
ment due to Alzheimer’s disease (AD). Optimal compliance and persistence with oral 
ChEIs are important to realize the beneﬁ cial outcomes of treatment initiation. The
current study quantiﬁ es compliance and persistence rates of oral ChEIs in an effort to 
understand the unmet therapeutic needs among patients with AD. METHODS: A
claims analysis was conducted from January 2004 through December 2006 using the
MedStat MarketScan database. Patients with q18 months of continuous insurance
coverage, newly initiated on an oral ChEI (no use in prior 6 months), q12 months 
follow up (F/U), and q1 diagnosis of AD (ICD-9 331.0, 290.0–290.3, 294.10–294.11)
were included. Compliance was estimated using medication possession ratio (MPR)
during the ﬁ rst 12 months of F/U. Persistence was deﬁ ned as continuous drug use 
without a gap of q30 days between medication reﬁ lls at any time after treatment initia-
tion. Proportion of compliant patients (MPR q0.8) and Kaplan-Meier rates of persis-
tence were calculated. RESULTS: Of the 4957 study patients, mean age was 80.3 years 
and 58.4% were females. A total of 385 (7.8%) patients switched ChEI during the 
ﬁ rst year of F/U. Mean (SD) number of reﬁ lls per patient was 7.5 (3.7) and mean (SD) 
duration of gap between reﬁ lls was 20.7 (31.9) days. Mean (median) MPR and propor-
tion of compliant patients were 0.74 (0.83) and 71%, respectively. Kaplan-Meier rates 
of persistence after 3, 6, 12, and 24 months were 79.0%, 60.3%, 40.1%, and 21.4%, 
respectively. CONCLUSIONS: Based on real-world data from a large cohort of AD 
patients initiated on ChEI, less than 50% were persistent on therapy during the ﬁ rst
year following ChEI treatment initiation. Further research is warranted to determine
whether transdermal patches might improve the persistence on ChEI therapy.
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OBJECTIVES: Early initiation of therapy with disease-modifying drugs (DMDs) is
important for the successful management of multiple sclerosis (MS). This study exam-
ined the time to ﬁ rst use of DMDs in newly diagnosed MS patients. METHODS: In
a post hoc analysis, newly diagnosed MS patients were identiﬁ ed using a national 
managed care database. Patients, aged 18 to 65 years, received their ﬁ rst MS diagnosis 
between July 1, 2000 and December 31, 2005 (index date), and were continuously
eligible for 6 months prior to the index date and 24 months after the index date. 
During the 24-month postindex period, subjects received q1 DMD (interferon beta
[IFNB]-1a intramuscular, IFNB-1b, glatiramer acetate, IFNB-1a subcutaneous, or 
natalizumab). The analysis did not include patients whose ﬁ rst DMD prescription was 
given after the study end date (December 31, 2007), or those who had used DMD in 
6 months preceding their ﬁ rst MS diagnosis. RESULTS: A total of 2522 MS patients 
(76.3% women) met the inclusion criteria for the study. The mean o standard devia-
tion patient age was 42.1 o 9.7 years. Most patients (47.9%) were from the Midwest, 
reﬂ ecting the national database sampling. The median time from ﬁ rst MS diagnosis
to ﬁ rst DMD use was 61.0 days; mean time was 140.2 o 171.9 days. When the time 
to ﬁ rst treatment was examined in 30-day increments, the results showed that 27.8%
received their ﬁ rst DMD in 30 days, 49.0% in 60 days, 59.6% in 90 days, and
74.2% in 180 days. One of every 4 patients (25.8%) did not initiate DMD for q180 
days following their ﬁ rst diagnosis. CONCLUSIONS: The ﬁ ndings of this analysis 
suggest that newly diagnosed MS patients often delay initiating DMD therapy.
